Last 12 months
Inside the activity.
18 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 2 | 0 |
| Jul 2026 | 8 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 7 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2022 Filed Jun 28, 2022 10:21 UTC |
Titterton Lewis H jrDirector
|
Exercise / conversionCommon Stock | 30,000 | $2.58 | $77,250.00 |
DisclosureSEC source: 0001493152-22-017926 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2022 Filed May 2, 2022 09:48 UTC |
Catelani MichaelPresident
|
OtherCommon Stock | 1,086 | $2.76 | $2,997.36 |
DisclosureSEC source: 0001493152-22-011741 · ownership.xml · nonDerivative · entry 1 Catelani Michael · CIK 0001689394 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,221 F1 · kind: The reporting person purchased the shares of common stock reported hereunder pursuant to the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the "Plan") which satisfies the requirements of Section 423 of the Internal Revenue Code. The reporting person's purchase of the shares of common stock is exempt from Section 16(b) under Rule 16b-3(c) and is exempt from the reporting requirements of Section 16 by virtue of Rule 16a-3(f)(1)(i)(B), however the reporting person has elected to voluntarily report the acquisition of the shares. F2 · price: In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on April 29, 2022. Read SEC document |
| April 26, 2022 Filed Apr 27, 2022 10:01 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 10,000 | $2.79 | $27,900.00 |
DisclosureSEC source: 0001493152-22-011291 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 988,070 Read SEC document |
| April 21, 2022 Filed Apr 22, 2022 09:50 UTC |
Catelani MichaelPresident
|
PurchaseCommon Stock | 5,500 | $2.66 | $14,630.00 |
DisclosureSEC source: 0001493152-22-010689 · ownership.xml · nonDerivative · entry 1 Catelani Michael · CIK 0001689394 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,135 Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 11:28 UTC |
Catelani MichaelPresident
|
PurchaseCommon Stock | 2,509 | $2.53 | $6,347.77 |
DisclosureSEC source: 0001493152-22-010594 · ownership.xml · nonDerivative · entry 1 Catelani Michael · CIK 0001689394 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,635 Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 10:34 UTC |
Catelani MichaelPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001493152-22-010024 · ownership.xml · derivative · entry 1 Catelani Michael · CIK 0001689394 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-04-14 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning April 30, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:15 UTC |
Titterton Lewis H jrDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001493152-22-006627 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-10 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning March 31, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:15 UTC |
Catelani MichaelCOO & CFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001493152-22-006626 · ownership.xml · derivative · entry 1 Catelani Michael · CIK 0001689394 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-03-10 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning March 31, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:15 UTC |
Gottschalk EmilyDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001493152-22-006625 · ownership.xml · derivative · entry 1 Gottschalk Emily · CIK 0001791108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-10 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning March 31, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:15 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001493152-22-006624 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-03-10 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning March 31, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:15 UTC |
Baskies Arnold MDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001493152-22-006623 · ownership.xml · derivative · entry 1 Baskies Arnold M · CIK 0001683567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-10 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning March 31, 2022. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 10:23 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 5,000 | $3.28 | $16,400.00 |
DisclosureSEC source: 0001493152-22-001112 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,070 Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 09:54 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 2,000 | $3.20 | $6,400.00 |
DisclosureSEC source: 0001493152-22-001018 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,070 Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 09:21 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 6,000 | $3.08 | $18,480.00 |
DisclosureSEC source: 0001493152-22-000899 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,070 Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 10:32 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
PurchaseCommon Stock | 20,000 | $3.00 | $60,000.00 |
DisclosureSEC source: 0001493152-22-000640 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,000 Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 09:36 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 11,000 | $3.08 | $33,880.00 |
DisclosureSEC source: 0001493152-22-000767 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,070 Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 13:32 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 18,244 | $4.76 | $86,841.44 |
DisclosureSEC source: 0001493152-21-026841 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,070 Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 11:05 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
PurchaseCommon Stock | 2,000 | $4.77 | $9,540.00 |
DisclosureSEC source: 0001493152-21-026828 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,000 Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 09:56 UTC |
Catelani MichaelCOO & CFO
|
OtherCommon Stock | 743 | $4.04 | $3,001.72 |
DisclosureSEC source: 0001493152-21-026933 · ownership.xml · nonDerivative · entry 1 Catelani Michael · CIK 0001689394 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,126 F1 · kind: The reporting person purchased the shares of common stock reported hereunder pursuant to the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the "Plan") which satisfies the requirements of Section 423 of the Internal Revenue Code. The reporting person's purchase of the shares of common stock is exempt from Section 16(b) under Rule 16b-3(c) and is exempt from the reporting requirements of Section 16 by virtue of Rule 16a-3(f)(1)(i)(B), however the reporting person has elected to voluntarily report the acquisition of the shares. F2 · price: In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on May 3, 2021. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 09:00 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 30,000 | $4.21 | $126,300.00 |
DisclosureSEC source: 0001493152-21-017937 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,826 Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 13:08 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
PurchaseCommon Stock | 5,000 | $4.28 | $21,400.00 |
DisclosureSEC source: 0001493152-21-017833 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,000 Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 09:56 UTC |
Baskies Arnold MDirector
|
PurchaseCommon Stock | 19,000 | $4.33 | $82,270.00 |
DisclosureSEC source: 0001493152-21-017817 · ownership.xml · nonDerivative · entry 1 Baskies Arnold M · CIK 0001683567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| July 16, 2021 Filed Jul 19, 2021 12:39 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 10,000 | $4.07 | $40,700.00 |
DisclosureSEC source: 0001493152-21-017157 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,826 Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 09:00 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
PurchaseCommon Stock | 10,000 | $3.94 | $39,400.00 |
DisclosureSEC source: 0001493152-21-017276 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,000 Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 12:45 UTC |
Gottschalk EmilyDirector
|
PurchaseCommon Stock | 20,065 | $3.96 | $79,457.40 |
DisclosureSEC source: 0001493152-21-017013 · ownership.xml · nonDerivative · entry 1 Gottschalk Emily · CIK 0001791108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,665 Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 11:22 UTC |
Baskies Arnold MDirector
|
PurchaseCommon Stock | 20,000 | $3.90 | $78,000.00 |
DisclosureSEC source: 0001493152-21-017005 · ownership.xml · nonDerivative · entry 1 Baskies Arnold M · CIK 0001683567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 12:39 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 2,200 | $3.65 | $8,030.00 |
DisclosureSEC source: 0001493152-21-017157 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,826 Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 11:19 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 23,300 | $3.72 | $86,676.00 |
DisclosureSEC source: 0001493152-21-016912 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,626 Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
Baskies Arnold MDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013457 · ownership.xml · derivative · entry 1 Baskies Arnold M · CIK 0001683567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
Titterton Lewis H jrDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013456 · ownership.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F3 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
Titterton Lewis H jrDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013456 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
Gottschalk EmilyDirector
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013455 · ownership.xml · derivative · entry 1 Gottschalk Emily · CIK 0001791108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
Catelani MichaelCOO & CFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013454 · ownership.xml · derivative · entry 2 Catelani Michael · CIK 0001689394 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F3 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
Catelani MichaelCOO & CFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013454 · ownership.xml · derivative · entry 1 Catelani Michael · CIK 0001689394 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable as follows: (i) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $5.00, (ii) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $6.00, (iii) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $7.00, and (iv) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $8.00. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013453 · ownership.xml · derivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F3 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 2,000,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013453 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable as follows: (i) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $5.00, (ii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $6.00, (iii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $7.00, and (iv) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $8.00. Read SEC document |
| May 31, 2021 Filed Jun 2, 2021 17:00 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
Disposition to issuerRestricted Stock Award · Derivative | 1,500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013453 · ownership.xml · derivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2021-05-31 F4 · derivative.exercise_date: The vesting requirements were not met and the restricted stock award expired on May 31, 2021. Read SEC document |
| April 30, 2021 Filed May 4, 2021 18:15 UTC |
Catelani MichaelCOO & CFO
|
OtherCommon Stock | 1,634 | $1.84 | $3,006.56 |
DisclosureSEC source: 0001493152-21-010447 · ownership.xml · nonDerivative · entry 1 Catelani Michael · CIK 0001689394 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,383 F1 · kind: The reporting person purchased the shares of common stock reported hereunder pursuant to the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the "Plan") which satisfies the requirements of Section 423 of the Internal Revenue Code. The reporting person's purchase of the shares of common stock is exempt from Section 16(b) under Rule 16b-3(c) and is exempt from the reporting requirements of Section 16 by virtue of Rule 16a-3(f)(1)(i)(B), however the reporting person has elected to voluntarily report the acquisition of the shares. F2 · price: In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on November 2, 2020. Read SEC document |
| April 23, 2021 Filed Apr 23, 2021 12:04 UTC |
Gottschalk EmilyDirector
|
PurchaseCommon Stock | 10,000 | $4.49 | $44,900.00 |
DisclosureSEC source: 0001493152-21-009519 · ownership.xml · nonDerivative · entry 1 Gottschalk Emily · CIK 0001791108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 13:27 UTC |
Baskies Arnold MDirector
|
PurchaseCommon Stock | 10,000 | $3.91 | $39,100.00 |
DisclosureSEC source: 0001493152-21-009223 · ownership.xml · nonDerivative · entry 1 Baskies Arnold M · CIK 0001683567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 10:32 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 5,000 | $3.99 | $19,950.00 |
DisclosureSEC source: 0001493152-21-009211 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,326 Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 15:56 UTC |
Baskies Arnold MDirector
|
PurchaseCommon Stock | 10,000 | $4.80 | $48,000.00 |
DisclosureSEC source: 0001493152-21-006789 · ownership.xml · nonDerivative · entry 1 Baskies Arnold M · CIK 0001683567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 13:43 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
PurchaseCommon Stock | 5,000 | $4.86 | $24,300.00 |
DisclosureSEC source: 0001493152-21-006780 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,000 Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 11:06 UTC |
Titterton Lewis H jrDirector
|
PurchaseCommon Stock | 45,000 | $4.84 | $217,800.00 |
DisclosureSEC source: 0001493152-21-006895 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,326 Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 09:41 UTC |
Gottschalk EmilyDirector
|
PurchaseCommon Stock | 15,600 | $4.88 | $76,128.00 |
DisclosureSEC source: 0001493152-21-006891 · ownership.xml · nonDerivative · entry 1 Gottschalk Emily · CIK 0001791108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,600 Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 16:44 UTC |
Titterton Lewis H jrDirector
|
GiftCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-002803 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,326 F1 · kind: Comprised of two separate bona fide gift transactions exempt under Rule 16b-5. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 09:00 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
PurchaseCommon Stock | 10,000 | $3.73 | $37,300.00 |
DisclosureSEC source: 0001493152-21-002176 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,000 Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 18:12 UTC |
Catelani MichaelCOO & CFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001493152-20-024386 · ownership.xml · derivative · entry 1 Catelani Michael · CIK 0001689394 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-23 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning December 31, 2020. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 18:10 UTC |
KUMAR AMITDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001493152-20-024384 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-12-23 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning December 31, 2020. Read SEC document |
| October 31, 2020 Filed Nov 3, 2020 17:06 UTC |
Catelani MichaelCOO & CFO
|
OtherCommon Stock | 1,918 | $1.56 | $2,992.08 |
DisclosureSEC source: 0001493152-20-020408 · ownership.xml · nonDerivative · entry 1 Catelani Michael · CIK 0001689394 · COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,749 F1 · kind: The reporting person purchased the shares of common stock reported hereunder pursuant to the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the "Plan") which satisfies the requirements of Section 423 of the Internal Revenue Code. The reporting person's purchase of the shares of common stock is exempt from Section 16(b) under Rule 16b-3(c) and is exempt from the reporting requirements of Section 16 by virtue of Rule 16a-3(f)(1)(i)(B), however the reporting person has elected to voluntarily report the acquisition of the shares. F2 · price: In accordance with the Plan, the shares were purchased based on 85% of the closing price of Anixa Biosciences, Inc. common stock on May 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.